Market Access Impact (EU5) [Parkinson's Disease]
Is patient preference costing your brand market share?
Market barriers affect nearly 15% of Parkinson’s disease prescriptions in the EU5 countries, causing half of the 8 brands we surveyed to lose market share while the other half gain. Patient-related barriers are the main culprits, but understanding the unique combination of barriers and competitive dynamics your brand faces is critical if you want to win back your lost share.
Learn how 7 barriers affect your market share, see who you take share from, and who gets your lost share in Market Access Impact: Parkinson’s Disease (EU5).
Based on a survey of 150 neurologists from the EU5 countries, the report covers 8 major therapies from Abbvie, Britannia Pharmaceuticals, GlaxoSmithKline, Novartis, Pfizer, Stada, Teva, UCB, and Zambon.
Top Takeaways
Market Access Impact: Parkinson’s Disease (US) explores key issues affecting drug manufacturers. You’ll learn:
How barriers affect market access:
We surveyed 100 US-based neurologists, chosen from the largest community of validated physicians in the world.
All respondents have:
MONEY BACK GUARANTEE!
At FirstWord, we stand behind our reports. If you're not completely satisfied, we’ll refund your money. Guaranteed.
About FirstWord
FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.
FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company’s success.
FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.
Market barriers affect nearly 15% of Parkinson’s disease prescriptions in the EU5 countries, causing half of the 8 brands we surveyed to lose market share while the other half gain. Patient-related barriers are the main culprits, but understanding the unique combination of barriers and competitive dynamics your brand faces is critical if you want to win back your lost share.
Learn how 7 barriers affect your market share, see who you take share from, and who gets your lost share in Market Access Impact: Parkinson’s Disease (EU5).
Based on a survey of 150 neurologists from the EU5 countries, the report covers 8 major therapies from Abbvie, Britannia Pharmaceuticals, GlaxoSmithKline, Novartis, Pfizer, Stada, Teva, UCB, and Zambon.
Top Takeaways
- Barriers affect nearly 15% of prescriptions: Almost all of that impact is due to patient-related barriers and cost.
- As many brands gain share as lose it: 4 of the surveyed brands lose share because of barriers, the other 4 gain.
- Patient-type restrictions are a big problem for two brands: Nearly 40% of doctors can’t prescribe these brands because they’re only recommended for certain patient type.
- One brand is too expensive: Roughly a quarter of doctors can’t prescribe it due to cost. By comparison, fewer than 10% experience cost barriers with any other surveyed brand.
- Another brand has a huge perception problem: More than half of surveyed doctors would not consider prescribing it.
- Doctors experience few barriers overall: 65% or more of surveyed doctors only experience 1 barrier or less with any given brand.
- Apokinon (apomorphine SC; Britannia Pharmaceuticals/Stada)
- Azilect (rasagiline; Teva)
- Comtan (entacapone; Novartis)
- Dostinex (cabergoline; Pfizer)
- Duodopa (levodopa/carbidopa intraduodenal; Abbvie)
- Neupro (rotigotine; UCB)
- Requip (ropinirole; GlaxoSmithKline)
- Xadago (safinamide; Zambon)
Market Access Impact: Parkinson’s Disease (US) explores key issues affecting drug manufacturers. You’ll learn:
How barriers affect market access:
- What brands do doctors prescribe the most?
- How many prescriptions do barriers affect?
- Which barriers have the biggest impact?
- How many doctors prescribe your brand? How many don’t, but would consider it?
- Why don’t doctors prescribe your brand? What do they prescribe instead?
- Which competing brands does your brand take market share from?
We surveyed 100 US-based neurologists, chosen from the largest community of validated physicians in the world.
All respondents have:
- Been practicing for 2+ years
- Prescribed at least one of the listed products
- Seen at least 5 patients with Parkinson’s disease in the last month
MONEY BACK GUARANTEE!
At FirstWord, we stand behind our reports. If you're not completely satisfied, we’ll refund your money. Guaranteed.
About FirstWord
FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.
FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company’s success.
FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.
1.WHAT ARE MARKET BARRIERS?
2.ABOUT THIS REPORT
3.ABOUT THE SURVEY
4.BRANDS INCLUDED IN THE SURVEY
5.EXECUTIVE SUMMARY
2.ABOUT THIS REPORT
3.ABOUT THE SURVEY
4.BRANDS INCLUDED IN THE SURVEY
5.EXECUTIVE SUMMARY
